Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes

Clinical and Vaccine Immunology

Volumn 16, Issue 12, 2009, Pages 1829-1831

  Bernardo, Lidice ^a   Fleitas, Osmel ^a   Pavón, Alequis ^a   Hermida, Lisset ^b   Guillén, Gerardo ^b   Guzman, Maria G ^a  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; HYBRID PROTEIN PD10; HYBRID PROTEIN PD5; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS; GENOTYPE; IMMUNIZATION; MONKEY; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SERODIAGNOSIS; VIRUS NEUTRALIZATION; VIRUS PLAQUE; VIRUS STRAIN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; GENOTYPE; MACACA FASCICULARIS; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; VIRAL ENVELOPE PROTEINS;

EID: 73449142827     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00191-09     Document Type: Article

References (28)

1. Alvarez, M., A. Pavon-Oro, R. Rodriguez-Roche, L. Bernardo, L. Morier, L. Sanchez, A. M. Alvarez, and M. G. Guzman. 2008. Neutralizing antibody response variation against dengue 3 strains. J. Med. Virol. 80:1783-1789.
2. Alvarez, M., R. Rodriguez-Roche, L. Bernardo, L. Morier, and G. Guzman. 2005. Improved dengue virus plaque formation on BHK21 and LLCMK2 cells: evaluation of some factors. Dengue Bull. 29:1-9.
3. Bernardo, L., A. Izquierdo, M. Alvarez, D. Rosario, I. Prado, C. López, R. Martínez, J. Castro, E. Santana, L. Hermida, G. Guillen, and M. Guzmán. 2008. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in nonhuman primates. Antivir. Res. 80:194-199.
4. Bernardo, L., A. Izquierdo, I. Prado, D. Rosario, M. Alvarez, E. Santana, J. Castro, R. Martinez, R. Rodriguez, L. Morier, G. Guillen, and M. G. Guzman. 2008. Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin. Vaccine Immunol. 15:439-446.
5. Bernardo, L., A. Yndart, S. Vazquez, L. Morier, and M. G. Guzman. 2005. Antibody responses to Asian and American genotypes of dengue 2 virus in immunized mice. Clin. Diagn. Lab. Immunol. 12:361-362.
6. Chu, J. J., R. Rajamanonmani, J. Li, R. Bhuvanakantham, J. Lescar, and M. L. Ng. 2005. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J. Gen. Virol. 86:405-412.
7. Falconar, A. K. 2008. Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines. Clin. Vaccine Immunol. 15:549-561.
8. Gromowski, G. D., and A. D. Barrett. 2007. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366:349-360.
9. Gromowski, G. D., N. D. Barrett, and A. D. Barrett. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82:8828-8837.
10. Hermida, L., L. Bernardo, J. Martin, M. Alvarez, I. Prado, C. Lopez, L. Sierra Bde, R. Martinez, R. Rodriguez, A. Zulueta, A. B. Perez, L. Lazo, D. Rosario, G. Guillen, and M. G. Guzman. 2006. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24:3165-3171.
11. Hiramatsu, K., M. Tadano, R. Men, and C. J. Lai. 1996. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. Virology 224:437-445.
12. Hombach, J., M. J. Cardosa, A. Sabchareon, D. W. Vaughn, and A. D. Barrett. 2007. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 25:4130-4139.
13. Kaufman, B. M., P. L. Summers, D. R. Dubois, and K. H. Eckels. 1987. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 36:427-434.
14. Kliks, S. C., S. Nimmanitya, A. Nisalak, and D. S. Burke. 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38:411-419.
15. Kochel, T. J., D. M. Watts, A. S. Gozalo, D. F. Ewing, K. R. Porter, and K. L. Russell. 2005. Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys. J. Infect. Dis. 191:1000-1004.
16. Kochel, T. J., D. M. Watts, S. B. Halstead, C. G. Hayes, A. Espinoza, V. Felices, R. Caceda, C. T. Bautista, Y. Montoya, S. Douglas, and K. L. Russell. 2002. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 360:310-312.
17. Laille, M., and C. Roche. 2004. Comparison of dengue-1 virus envelope glycoprotein gene sequences from French Polynesia. Am. J. Trop. Med. Hyg. 71:478-484.
18. Leitmeyer, K. C., D. W. Vaughn, D. M. Watts, R. Salas, I. Villalobos, de Chacon, C. Ramos, and R. Rico-Hesse. 1999. Dengue virus structural differences that correlate with pathogenesis. J. Virol. 73:4738-4747.
19. Lin, B., C. R. Parrish, J. M. Murray, and P. J. Wright. 1994. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 202:885-890.
20. Morens, D. M., S. B. Halstead, P. M. Repik, R. Putvatana, and N. Raybourne. 1985. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J. Clin. Microbiol. 22:250-254.
21. Rey, F. A. 2003. Dengue virus envelope glycoprotein structure: new insight into its interactions during viral entry. Proc. Natl. Acad. Sci. USA 100:6899-6901.
22. Rey, F. A., F. X. Heinz, C. Mandl, C. Kunz, and S. C. Harrison. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 375:291-298.
23. Rico-Hesse, R. 2007. Dengue virus evolution and virulence models. Clin. Infect. Dis. 44:1462-1466.
24. Sukupolvi-Petty, S., S. K. Austin, W. E. Purtha, T. Oliphant, G. E. Nybakken, J. J. Schlesinger, J. T. Roehrig, G. D. Gromowski, A. D. Barrett, D. H. Fremont, and M. S. Diamond. 2007. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81:12816-12826.
25. Volk, D. E., Y. C. Lee, X. Li, V. Thiviyanathan, G. D. Gromowski, L. Li, A. R. Lamb, D. W. Beasley, A. D. Barrett, and D. G. Gorenstein. 2007. Solution structure of the envelope protein domain III of dengue-4 virus. Virology 364:147-154.
26. Wong, S. S., J. Abd-Jamil, and S. Abubakar. 2007. Antibody neutralization and viral virulence in recurring dengue virus type 2 outbreaks. Viral Immunol. 20:359-368.
27. Zulueta, A., L. Hermida, L. Lazo, I. Valdes, R. Rodriguez, C. Lopez, R. Silva, D. Rosario, J. Martin, M. G. Guzman, and G. Guillen. 2003. The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein influence some parameters of the resulting chimeric constructs. Biochem. Biophys. Res. Commun. 308:619-626.
28. Zulueta, A., J. Martin, L. Hermida, M. Alvarez, I. Valdes, I. Prado, G. Chinea, D. Rosario, G. Guillen, and M. G. Guzman. 2006. Amino acid changes in the recombinant dengue 3 envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res. 121:65-73.